The investment is part of CGT Catapult’s Cross-Catapult Investment Pilot and will accelerate the pre-clinical development of Spliceor’s trans-splicing gene therapy platform.
On July 22, 2025, the
The pilot program’s investment in Spliceor will support the development and validation of the company’s trans-splicing gene therapy platform for cancer and other treatments.
“Spliceor is an innovative advanced therapies company with the potential to develop a life-changing gene therapy to benefit patients,”
“We are grateful to receive this significant investment, which recognizes Spliceor’s potential to transform lives through innovative gene therapies,”
An investment committee will assess potential future investments in advanced therapies developed in the UK.
CGT Catapult is an independent organization working for the advancement of cell and gene therapies. On July 16, 2025, CGT Catapult responded to the UK government’s Life Sciences Sector Plan (2), which was published on July 16, 2025, and aligns the government’s industrial strategy with its health mission. The strategy was created in coordination with industry organizations, life sciences businesses, and patient groups and focuses on enabling R&D, promoting investment in life sciences, and reforming the National Health Service.
“Encouraging investment in the sector through the British Business Bank will support start-ups and early-stage companies access the finance they need to continue their journey to commercialization,” Durdy said in a press release (3). “The Government aims for more scale-up finance being raised by life sciences businesses in the UK than anywhere else in Europe by 2030. This access to finance is vital to ensure that there is a flow of new medicines and ideas coming through from our research base into development and ultimately reaching the patients who need them.”
“Advanced therapies can be life-changing for patients, providing relief from diseases where there may not be effective alternative treatment options, and they have potential to be a crucial part of the Government's ambition to make life sciences a cornerstone of economic renewal and a healthier UK,” Durdy continued in the statement. “We look forward to continuing our work with Government, industry, and the healthcare sector, and contributing to the success of the UK life sciences ecosystem.”
